Menu
Search
|

Menu

Close
X

Verona Pharma PLC VRNA.OQ (NASDAQ Stock Exchange Global Market)

14.55 USD
+1.90 (+15.02%)
As of Feb 23
chart
Previous Close 12.65
Open 13.95
Volume 1,429
3m Avg Volume 1,256
Today’s High 14.87
Today’s Low 13.95
52 Week High 17.50
52 Week Low 10.44
Shares Outstanding (mil) 105.02
Market Capitalization (mil) 139.15
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, GBP)
FY17
0
FY16
0
FY15
0
EPS (GBP)
FY17
-0.160
FY16
-0.153
FY15
-0.371
*Note: Units in Millions of British Pounds
**Note: Units in British Pounds

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.59
Price to Sales (TTM)
vs sector
--
8.08
Price to Book (MRQ)
vs sector
1.63
5.24
Price to Cash Flow (TTM)
vs sector
--
25.98
Total Debt to Equity (MRQ)
vs sector
0.00
15.60
LT Debt to Equity (MRQ)
vs sector
0.00
12.18
Return on Investment (TTM)
vs sector
--
13.67
Return on Equity (TTM)
vs sector
--
15.40

EXECUTIVE LEADERSHIP

David Ebsworth
Non-Executive Chairman of the Board, Since 2014
Salary: £6,667.00
Bonus: --
Sven Karlsson
Chief Executive Officer, Executive Director, Since 2012
Salary: £180,000.00
Bonus: £81,667.00
Kenneth Newman
Chief Medical Officer, Since 2015
Salary: --
Bonus: --
Ben Harber
Company Secretary, Since 2013
Salary: --
Bonus: --
Kenneth Cunningham
Non-Executive Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3 More London Riverside
LONDON     SE1 2RE

Phone: +4420.32834200

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.

SPONSORED STORIES